National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Niraparib (Zejula®) which is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response [CR] or partial response [PR]) to platinum-based chemotherapy.

NCPE Assessment Process Complete
Rapid review commissioned 01/06/2018
Rapid review completed 21/06/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 27/06/2018